ZNF667-AS1

Summary

ZNF667-AS1 (ZNF667 antisense RNA 1, HGNC:44321) is a long non-coding RNA gene on chromosome 19q13.43.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:44321
Approved symbol	ZNF667-AS1
Name	ZNF667 antisense RNA 1
Location	19q13.43
Locus type	RNA, long non-coding
Status	Approved
Aliases	MORT
Ensembl gene	ENSG00000166770
Ensembl biotype	lncRNA
Entrez	100128252
RNAcentral	URS000075E697 — lncRNA, 1837 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 27 lncRNA

ENST00000585445, ENST00000586091, ENST00000586822, ENST00000588158, ENST00000588685, ENST00000591797, ENST00000592146, ENST00000594783, ENST00000601875, ENST00000654200, ENST00000654382, ENST00000661902, ENST00000664785, ENST00000665045, ENST00000667367, ENST00000669162, ENST00000670294, ENST00000685306, ENST00000691191, ENST00000693493, ENST00000809477, ENST00000809478, ENST00000809479, ENST00000809480, ENST00000809481, ENST00000809482, ENST00000809483

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000585445 — 2 exons

Exon	Start	End
ENSE00002776055	56478131	56478381
ENSE00002932064	56494163	56495432

Expression profiles

Bgee: expression breadth ubiquitous, 248 present calls, max score 98.80.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.8339 / max 185.1596, expressed in 1328 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177720	11.5282	1327
177719	1.0558	504
177721	0.2500	109

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	98.80	gold quality
nucleus accumbens	UBERON:0001882	96.75	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.42	gold quality
primary visual cortex	UBERON:0002436	96.37	gold quality
middle temporal gyrus	UBERON:0002771	96.37	gold quality
caudate nucleus	UBERON:0001873	96.20	gold quality
cortical plate	UBERON:0005343	96.19	gold quality
putamen	UBERON:0001874	96.18	gold quality
hypothalamus	UBERON:0001898	96.05	gold quality
anterior cingulate cortex	UBERON:0009835	96.05	gold quality
amygdala	UBERON:0001876	95.92	gold quality
epithelial cell of pancreas	CL:0000083	95.76	silver quality
cerebellar vermis	UBERON:0004720	95.67	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.64	gold quality
pituitary gland	UBERON:0000007	95.63	gold quality
right frontal lobe	UBERON:0002810	95.52	gold quality
pons	UBERON:0000988	95.50	gold quality
adenohypophysis	UBERON:0002196	95.46	gold quality
occipital lobe	UBERON:0002021	95.35	gold quality
Ammon’s horn	UBERON:0001954	95.30	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.23	gold quality
forebrain	UBERON:0001890	95.16	gold quality
brain	UBERON:0000955	95.05	gold quality
substantia nigra	UBERON:0002038	94.91	gold quality
cerebellar cortex	UBERON:0002129	94.90	gold quality
cerebellum	UBERON:0002037	94.87	gold quality
temporal lobe	UBERON:0001871	94.86	gold quality
cerebellar hemisphere	UBERON:0002245	94.85	gold quality
right testis	UBERON:0004534	94.85	gold quality
cerebral cortex	UBERON:0000956	94.80	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 15)

• Data revealed deregulation of MORT expression due to DNA hypermethylation in 15 out of the 17 most common human cancers. (PMID:26646903)
• The epigenetic silencing of MORT (ZNF667-AS1) in a large majority of the common human cancers suggests a potential fundamental role in cellular immortalization during human carcinogenesis. (PMID:26646903)
• ZNF667-AS1 inhibited the proliferation of cervical cancer cells and was expected to be the biomarker and potential therapeutic target for predicting cervical cancer and determining its prognosis. (PMID:29243775)
• Aberrant hypermethylation-mediated downregulation of antisense lncRNA ZNF667-AS1 and its sense gene ZNF667 correlate with progression and prognosis of esophageal squamous cell carcinoma. (PMID:31804468)
• LncRNAMORT is upregulated in myocardial infarction and promotes the apoptosis of cardiomyocyte by downregulating miR-93. (PMID:32450811)
• lncRNA ZNF667-AS1 (NR_036521.1) inhibits the progression of colorectal cancer via regulating ANK2/JAK2 expression. (PMID:32853419)
• Analysis of Long Noncoding RNA ZNF667-AS1 as a Potential Biomarker for Diagnosis and Prognosis of Glioma Patients. (PMID:33282010)
• LncRNA MORT Overexpression Inhibits Cancer Cell Migration and Invasion in Hepatocellular Carcinoma by Downregulating NOTCH1. (PMID:33493420)
• ZNF667-AS1, a positively regulating MEGF10, inhibits the progression of uveal melanoma by modulating cellular aggressiveness. (PMID:33512044)
• IncRNA ZNF667-AS1 Suppresses Epithelial Mesenchymal Transformation by Targeting TGF-beta1 in Oral Squamous Cell Carcinoma. (PMID:34258957)
• Hypermethylation of Genes in New Long Noncoding RNA in Ovarian Tumors and Metastases: A Dual Effect. (PMID:34292442)
• LncRNA ZNF667-AS1 alleviates rheumatoid arthritis by sponging miR-523-3p and inactivating the JAK/STAT signalling pathway. (PMID:34423698)
• LncRNA MORT negatively regulates FGF1 to suppress malignant progression of breast cancer. (PMID:34730198)
• Regulation of IncRNA ZNF667-AS1 in Proliferation and Invasion of Esophageal Squamous Cell Carcinoma Cells via Mediating ceRNA Network. (PMID:35997118)
• LncRNA ZNF667-AS1 Targets miR-523-3p/KIF5C Axis to Hinder Colon Cancer Progression. (PMID:37322260)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.